BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19808872)

  • 1. Loss of SNF5 expression correlates with poor patient survival in melanoma.
    Lin H; Wong RP; Martinka M; Li G
    Clin Cancer Res; 2009 Oct; 15(20):6404-11. PubMed ID: 19808872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
    Wang Y; Dai DL; Martinka M; Li G
    Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
    Klochendler-Yeivin A; Picarsky E; Yaniv M
    Mol Cell Biol; 2006 Apr; 26(7):2661-74. PubMed ID: 16537910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
    Caramel J; Medjkane S; Quignon F; Delattre O
    Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of cytoplasmic p27 expression in human melanoma.
    Chen G; Cheng Y; Zhang Z; Martinka M; Li G
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
    Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
    Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in gene expression profiles in multiple myeloma cells after knocking-down SNF5, a core subunit of SWI/SNF complex].
    Xie Y; Xu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 May; 33(5):667-71. PubMed ID: 23688984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.
    McKenna ES; Tamayo P; Cho YJ; Tillman EJ; Mora-Blanco EL; Sansam CG; Koellhoffer EC; Pomeroy SL; Roberts CW
    Cell Cycle; 2012 May; 11(10):1956-65. PubMed ID: 22544318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation.
    Gresh L; Bourachot B; Reimann A; Guigas B; Fiette L; Garbay S; Muchardt C; Hue L; Pontoglio M; Yaniv M; Klochendler-Yeivin A
    EMBO J; 2005 Sep; 24(18):3313-24. PubMed ID: 16138077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of PIH1D1 on the degradation of its binding protein SNF5].
    Zhai N; Zhang Y; Shen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Dec; 31(6):756-9. PubMed ID: 20078948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRG1 expression is increased in human cutaneous melanoma.
    Lin H; Wong RP; Martinka M; Li G
    Br J Dermatol; 2010 Sep; 163(3):502-10. PubMed ID: 20491765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler.
    Woodley CM; Romer AS; Wang J; Guarnaccia AD; Elion DL; Maxwell JN; Guerrazzi K; McCann TS; Popay TM; Matlock BK; Flaherty DK; Lorey SL; Liu Q; Tansey WP; Weissmiller AM
    Oncogene; 2021 May; 40(20):3593-3609. PubMed ID: 33931740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
    Dai DL; Martinka M; Li G
    J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Tip60 in human melanoma cell migration, metastasis, and patient survival.
    Chen G; Cheng Y; Tang Y; Martinka M; Li G
    J Invest Dermatol; 2012 Nov; 132(11):2632-41. PubMed ID: 22673729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
    Guo H; Cheng Y; Martinka M; McElwee K
    Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.
    Isakoff MS; Sansam CG; Tamayo P; Subramanian A; Evans JA; Fillmore CM; Wang X; Biegel JA; Pomeroy SL; Mesirov JP; Roberts CW
    Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17745-50. PubMed ID: 16301525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
    Lu J; Zhang G; Cheng Y; Tang Y; Dong Z; McElwee KJ; Li G
    Oncol Rep; 2014 Dec; 32(6):2571-9. PubMed ID: 25310020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PUMA expression is significantly reduced in human cutaneous melanomas.
    Karst AM; Dai DL; Martinka M; Li G
    Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.
    Stockman DL; Curry JL; Torres-Cabala CA; Watson IR; Siroy AE; Bassett RL; Zou L; Patel KP; Luthra R; Davies MA; Wargo JA; Routbort MA; Broaddus RR; Prieto VG; Lazar AJ; Tetzlaff MT
    J Cutan Pathol; 2015 May; 42(5):308-17. PubMed ID: 25754356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma.
    Karjalainen JM; Kellokoski JK; Eskelinen MJ; Alhava EM; Kosma VM
    J Clin Oncol; 1998 Nov; 16(11):3584-91. PubMed ID: 9817279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.